Substantia Nigra Pars Compacta in Parkinson's Disease

TREM2-Expressing Microglia

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Substantia Nigra Pars Compacta in Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Substantia Nigra Pars Compacta in Parkinson's Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Introduction

[TREM2](/proteins/trem2)-expressing [microglia](/cell-types/microglia-neuroinflammation) represent a specialized population of brain immune cells that play a critical role in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. These cells express the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which is essential for microglial survival, phagocytosis, and inflammatory responses. [@guerreiro2013]

Overview

TREM2-Expressing Microglia

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Substantia Nigra Pars Compacta in Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Substantia Nigra Pars Compacta in Parkinson's Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Introduction

[TREM2](/proteins/trem2)-expressing [microglia](/cell-types/microglia-neuroinflammation) represent a specialized population of brain immune cells that play a critical role in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. These cells express the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which is essential for microglial survival, phagocytosis, and inflammatory responses. [@guerreiro2013]

Overview

TREM2-expressing microglia are a subset of microglia that express the TREM2 receptor on their surface. TREM2 is a cell surface receptor belonging to the immunoglobulin superfamily that is expressed exclusively on myeloid cells including microglia in the brain. [@jonsson2013]

The TREM2 pathway has become one of the most important therapeutic targets in Alzheimer's disease: [@kerenshaul2017]

• TREM2 variants increase AD risk by 3-4 fold
• TREM2 is required for amyloid plaque clearance
• TREM2 dysfunction leads to neuroinflammation
• TREM2 agonists are in clinical development

Morphology and Markers

• Cell Type: Activated microglia
• Marker Genes: TREM2, CD33, CX3CR1, IBA1 (AIF1)
• Neurotransmitter: Not applicable (immune cells)
• Morphology: Amoeboid shape with multiple branching processes, enlarged soma in disease states
• Location: Throughout brain parenchyma, enriched around amyloid plaques

Normal Function

TREM2-expressing microglia perform critical homeostatic functions: [@ulgen2020]

Phagocytosis

• Amyloid clearance: TREM2 mediates uptake of [amyloid-beta](/proteins/amyloid-beta)
• Apoptotic cell clearance: Engulfment of dead [neurons](/entities/neurons)
• Synaptic pruning: Developmental synapse elimination
• Lipid metabolism: Processing of myelin debris

Survival and Proliferation

• Energy metabolism: TREM2 supports microglial metabolic fitness
• Cell survival: Prevents [apoptosis](/entities/apoptosis) under stress
• Proliferation: Supports microglial expansion in disease

Inflammatory Response

• Cytokine production: Modulates inflammatory mediator release
• [NF-κB](/entities/nf-kb) signaling: TREM2 regulates inflammatory pathways
• Complement activation: Involved in complement cascade

TREM2 Signaling

Ligands

• Amyloid-beta: Direct binding to TREM2
• Lipids: Apolipoproteins, especially [APOE](/proteins/apoe)
• Phosphatidylserine: On apoptotic cells
• [Heat shock proteins](/entities/heat-shock-proteins): Released from stressed cells

Downstream Pathways

• DAP12: TREM2 signals through TYROBP/DAP12 adaptor protein
• PI3K/Akt: Survival signaling
• MAPK pathways: Inflammatory response
• [mTOR](/mechanisms/mtor-signaling-pathway): Metabolic regulation

Vulnerability in Disease

Alzheimer's Disease

TREM2 microglia show disease-specific changes: [@song2023]

• Risk variants: TREM2 R47H, R62H increase AD risk 3-4 fold
• Plaque association: TREM2+ microglia surround amyloid plaques ("disease-associated microglia" or DAM)
• Impaired clearance: TREM2 variants reduce amyloid phagocytosis
• Neuroinflammation: Dysregulated inflammatory response

Parkinson's Disease

• Synucleinopathy: TREM2 may affect [alpha-synuclein](/proteins/alpha-synuclein) clearance
• Neuroinflammation: TREM2 modulates microglial response
• Genetic interaction: TREM2 variants may modify PD risk

Amyotrophic Lateral Sclerosis (ALS)

• Motor neuron disease: TREM2 is upregulated in ALS microglia
• Inflammatory response: TREM2 modulates neuroinflammation
• Genetic variants: TREM2 associations with ALS risk

Nasu-Hakola Disease

• Rare disorder: TREM2 or TYROBP mutations cause this disease
• Premature dementia: Early-onset frontal lobe dementia
• Bone cysts: Polycystic lipomembranous osteodysplasia

Disease-Associated Microglia (DAM)

TREM2-expressing microglia transition to a DAM state in neurodegeneration:

Stage 1 DAM

• Triggered by: TREM2 activation
• Features: Upregulated phagocytic genes
• Function: Attempted amyloid clearance

Stage 2 DAM

• Triggered by: Prolonged disease stress
• Features: Pro-inflammatory phenotype
• Function: May become dysfunctional

Dysfunctional TREM2 Microglia

• Reduced phagocytosis: Impaired amyloid clearance
• Enhanced inflammation: Excessive cytokine release
• Metabolic stress: Energy depletion
• Neurotoxicity: May contribute to neuronal loss

Therapeutic Implications

TREM2 Agonists

• Purpose: Enhance microglial function
• Examples: AL002, AZD8329
• Status: Clinical trials in AD

TREM2 Antagonists

• Purpose: Reduce excessive inflammation
• Potential: May help if overactivated

APOE Modulation

• Rationale: APOE is a TREM2 ligand
• Approach: APOE-targeting therapies

Biomarkers

Genetic Testing

• TREM2 variants: R47H, R62H increase risk
• Genetic counseling: For at-risk individuals

Fluid Biomarkers

• sTREM2: Soluble TREM2 in CSF
• Levels: Changes in AD progression

Imaging

• PET: TSPO shows microglial activation
• MRI: Structural changes associated with inflammation

Research Methods

Models

• TREM2 knockouts: Mouse models for study
• iPSC models: Human microglia from patients
• Single-cell RNAseq: Profiling TREM2+ cells

Experimental Approaches

• CRISPR: Gene editing of TREM2
• Antibodies: TREM2-targeting therapeutics
• Flow cytometry: Isolating TREM2+ cells

Background

The study of Substantia Nigra Pars Compacta In [Parkinson'S Disease](/diseases/parkinsons-disease) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [Allen Brain Atlas - TREM2 expression](https://portal.brain-map.org/)
• [PubMed - TREM2 microglia](https://pubmed.ncbi.nlm.nih.gov/)
• [AlzForum - TREM2](https://www.alzforum.org/)